Published in Int J Cancer on April 15, 2007
Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol (2013) 1.72
Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer (2009) 1.24
Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol (2009) 1.21
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res (2008) 1.21
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One (2011) 1.19
Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch (2014) 1.15
Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol (2009) 1.13
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch (2014) 1.10
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? Oncologist (2012) 1.10
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis (2009) 1.08
The Critical Impact of HIF-1a on Gastric Cancer Biology. Cancers (Basel) (2013) 1.08
Notch signaling regulates gastric antral LGR5 stem cell function. EMBO J (2015) 0.99
Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol (2010) 0.99
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Mitochondria and energetic depression in cell pathophysiology. Int J Mol Sci (2009) 0.95
Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res (2009) 0.92
Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci (2012) 0.90
Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer. BMC Cancer (2010) 0.90
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) (2015) 0.89
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med (2013) 0.88
Molecular targeted therapies in advanced gastric cancer: does tumor histology matter? Therap Adv Gastroenterol (2013) 0.87
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Invest New Drugs (2013) 0.86
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer Chemother Pharmacol (2011) 0.86
Challenge for a better combination with basic evidence. Int J Clin Oncol (2008) 0.85
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int Neurourol J (2016) 0.84
AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther (2013) 0.83
Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth. Am J Pathol (2010) 0.82
mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer (2015) 0.81
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med (2013) 0.80
Autophagy: a primer for the gastroenterologist/hepatologist. Can J Gastroenterol (2011) 0.80
Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol (2016) 0.79
Gastric cancer: past progress and present challenges. Gastric Cancer (2014) 0.78
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest New Drugs (2010) 0.78
Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs (2016) 0.77
Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway. Int J Mol Med (2016) 0.77
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer (2015) 0.76
Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res (2016) 0.75
Targeting the Mammalian Target of Rapamycin in Lung Cancer. Am J Med Sci (2016) 0.75
Rapamycin and thalidomide treatment of a patient with refractory metastatic gastroesophageal adenocarcinoma: a case report. Oncologist (2010) 0.75
To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients. J Cancer (2016) 0.75
Drug development: Raise standards for preclinical cancer research. Nature (2012) 20.64
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2004) 10.55
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen (2004) 2.94
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res (2009) 2.93
Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res (2008) 2.75
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol (2009) 2.52
Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol (2008) 2.52
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30
Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene (2005) 2.24
Topographical anatomy of periprostatic and capsular nerves: quantification and computerised planimetry. Eur Urol (2008) 2.22
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer (2007) 2.12
Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol (2007) 2.02
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg (2004) 1.99
Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res (2006) 1.99
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol (2005) 1.94
Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell (2013) 1.93
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst (2004) 1.82
The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res (2007) 1.80
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res (2002) 1.78
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest (2006) 1.78
Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest (2002) 1.78
Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol (2008) 1.76
A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS One (2013) 1.74
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation (2004) 1.68
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer (2005) 1.64
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res (2005) 1.63
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer (2004) 1.62
Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res (2003) 1.61
Insulin treatment improves the systemic inflammatory reaction to severe trauma. Ann Surg (2004) 1.61
Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res (2004) 1.61
Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci (2009) 1.60
Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol (2005) 1.60
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg (2003) 1.56
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model. Radiology (2005) 1.55
Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb Haemost (2004) 1.55
GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol (2009) 1.54
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Association of antibodies to exocrine pancreas with subtypes of Crohn's disease. Eur J Gastroenterol Hepatol (2005) 1.53
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol (2006) 1.52
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Antiangiogenic therapy--evolving view based on clinical trial results. Nat Rev Clin Oncol (2012) 1.51
Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res (2005) 1.49
Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol (2003) 1.47
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest (2007) 1.47
Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg (2002) 1.47
p38 MAP kinase--a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J (2002) 1.46
Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol (2003) 1.45
Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol (2004) 1.45
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res (2002) 1.44
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol (2004) 1.42
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
Targeted therapy trials: approval strategies, target validation, or helping patients? J Clin Oncol (2007) 1.42
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
The effect of hepatocyte growth factor on gut mucosal apoptosis and proliferation, and cellular mediators after severe trauma. Surgery (2005) 1.42
Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther (2002) 1.42
Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. Oncogene (2005) 1.41
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol (2002) 1.41
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res (2008) 1.40
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39
Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology (2004) 1.39